



## Joost Boormans

Erasmus MC Cancer Institute, *Rotterdam, The Netherlands*

Professor Joost Boormans attended Medical School at the University of Utrecht, The Netherlands and graduated in 2001. In the same year, he passed the United States Medical Licensing Examination, Step 1 and 2. Following his rotations he was trained as a urologist at the department of Urology of the Erasmus Medical Centre Rotterdam, The Netherlands and affiliated hospitals. He finished his training in December 2009, after which he became a fellow in urological oncology at the department of Urology of Erasmus MC Cancer Institute. In February 2011, he obtained his PhD by successfully defending his thesis on 'Prognostic Implications of Important Genetic Alterations in Prostate Cancer' at the Erasmus University Rotterdam.

He was appointed as a urologist in Rotterdam in July 2011 and initiated the Erasmus MC Bladder Cancer Center as the center-of-expertise for the Southwestern part of The Netherlands, which covers a population of 3.0 million. In 2019 he was appointed associate professor and became Chair of Urology in 2021. From January 1<sup>st</sup>, 2023, he was appointed full professor at the Erasmus University Rotterdam, the Netherlands.

His main clinical interests are bladder cancer, upper tract urothelial cancer, and testicular cancer. He performs both robot-assisted and open pelvic and retroperitoneal surgery. His main research interests are the diagnosis, prognosis, and treatment of urothelial cancer.

He is the Chief Investigator for CHASIT, a multi-institutional phase II clinical trial assessing the benefit of sequential chemo-immunotherapy in advanced urothelial cancer patients. He is leading a European consortium on the molecular characterization of upper tract urothelial carcinoma and the SeARCH study on urinary diagnostics in patients referred for microhematuria.

He is also a board member of the Erasmus MC Cancer Institute, the national Prospective Bladder Cancer Infrastructure, the Scientific Congress Office of EAU, track leader on urothelial cancer, and he is also a member of the EAU Testicular Cancer guidelines panel. He has published over 120 peer-reviewed papers in international and national journals and invited speakers at national and international meetings on bladder cancer.